Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.31 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18776430 | 0.90 | ADORA3 (0.32) | ADORA3MEN1KMT2ADOT1L | |
| SCHEMBL18776429 | 0.89 | ADORA3 (0.31) | ADORA3MEN1KMT2ADOT1L | |
| SCHEMBL18776431 | 0.88 | ADORA2A (0.34) | ADORA3SLC29A1RXFP1 | |
| SCHEMBL18776462 | 0.85 | ADORA3 (0.36) | AHCYADORA3MEN1KMT2ADOT1L | |
| SCHEMBL18776426 | 0.81 | ADORA3 (0.43) | ADORA3 | |
| SCHEMBL18776422 | 0.81 | — | — | |
| SCHEMBL12022990 | 0.76 | MARS1 (0.34) | AHCYADORA3MEN1KMT2ADOT1L | |
| SCHEMBL12022986 | 0.74 | MARS1 (0.34) | ADORA3MEN1KMT2ADOT1L | |
| SCHEMBL12022998 | 0.73 | MARS1 (0.33) | ADORA3MEN1KMT2ADOT1L | |
| SCHEMBL18776436 | 0.73 | ADORA3 (0.40) | ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | BRADSHAW CURT W (US) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | AHCY 1175/4885ADORA3 3873/4885EHMT1 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.